Etapen
Etapen, also known as etapenimod, is a medication used to treat certain types of cancer. It is a type of kinase inhibitor, specifically targeting the Janus kinase (JAK) pathway, which is involved in the regulation of immune responses. Etapen is approved for the treatment of certain types of lymphoma, including mantle cell lymphoma and marginal zone lymphoma, as well as for the treatment of certain types of leukemia, such as chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML) in blast crisis.
The drug works by inhibiting the activity of JAK enzymes, which are involved in the signaling pathways
Etapen was first approved by the U.S. Food and Drug Administration (FDA) in 2016 for the treatment
Etapen is available under the brand name Jakafi and is manufactured by Blueprint Medicines. The drug is